Changzhou Filos Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Filos") is a Sino-foreign joint venture and innovative enterprise dedicated to biotechnology and new drug research and development. The research direction mainly focuses on cancer targeting and immunotherapy, and develops therapeutic original drugs including small molecule compounds, monoclonal antibodies, antibody-small molecule coupling molecules, and immune cells.
The establishment of Fellows is based on the needs of pharmaceutical innovation and research and development and aims at international standards. Its main core technology team members have more than 20 years of R&D management background in international famous pharmaceutical enterprises (such as GSK, etc.). The company has continuously improved its core competitiveness by building a characteristic biotechnology platform from a high starting point, and has built a super-large (1011) full-human combination antibody library suitable for large-scale screening and a therapeutic antibody screening and discovery platform CABTM based on phage display and cell function display technology; CCCTM, an original combinatorial cell bank technology platform suitable for the screening and optimization of chimeric antigen receptor (CAR). At the same time, it has independently developed and introduced many cutting-edge biological technologies such as site-directed mutation of unnatural amino acids, deletion and modification of CRISPR-CAS9 gene. Fellows currently has 9 independent patents, including 5 invention patents and 4 authorized patents.
As a company with innovative drug research and development as its core, the development goal of Fellows is to build an industrial chain of new drug research and development and transformation, and rapidly promote clinical trials by cooperating with leading international and domestic research institutes and companies to develop collaborative innovation.
During the entrepreneurial period, Fallos was awarded the "Leading Entrepreneurship Key Enterprise" of Changzhou City, the "Leading Talent of Changzhou City" key recommendation project of Changzhou City, the "Private Science and Technology Enterprise of Jiangsu Province", and established the "Foreign Academician Studio"; Dr. Yang Guang, the founder of the company, was awarded the titles of "National Thousand Talents Plan" entrepreneurial talents and "Jiangsu Provincial High-level Innovation and Entrepreneurship Talents" by the Central Organization Department.
Enterprise vision
Innovation, integrity, cooperation and human health are our responsibilities from the source.
Corporate mission
Corporate mission brings new hope to cancer patients and satisfies unmet clinical needs through the focus and innovation in the field of immunity (NK);
Enterprise values
Enterprise objectives
Develop internationally leading original monoclonal antibodies and immune cells, especially NK cell drugs in the field of tumor immunotherapy;
Love work, love work, be conscientious and responsible, and reflect self-worth in work;
Enjoy learning, improve personal ability and accomplishment in work, and realize self-development;
Respect others, work together and build a harmonious and friendly working environment.
HOME
